Mandate

Vinge has advised CTEK AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised CTEK AB (publ) (“CTEK” or the “Company”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on 13 September 2021 and the first day of trading on Nasdaq Stockholm was 24 September 2021.

The price in the offering was SEK 69 per share, corresponding to a market capitalization of all of CTEK’s shares upon completion of the offering of approximately SEK 3.4 billion. The offering comprised of 30,621,798 shares, of which 4,347,827 shares were newly issued shares and 26,273,971 shares were existing shares offered by Altor Fund III GP Limited and Faustina Ltd.

CTEK is the leading global supplier of premium low voltage chargers and the second largest EVSE product supplier in Sweden. CTEK was founded in Vikmanshyttan in 1997 and today has sales in more than 70 countries. Based on its technology leadership, the Company has established strong and longstanding customer relationships with more than 50 of the world’s most prestigious vehicle OEMs. In addition to OEMs, the Company also offers products to workshops, distributors, retailers, parking lots, charge point operators, property owners and consumers.

Vinge’s team primarily consisted of David Andersson, Joel Wahlberg, Amanda M Johansson, Olivia Belding and Lorin Arabi (Capital Markets and Public M&A), Elsie Nassar and Amanda Steen (M&A), Louise Brorsson Salomon, Seyran Sahin and Felix Möller (Banking and Finance), Martin Boström and Jolene Reimerson (Corporate Commercial), Tove Lövgren Frisk (Compliance) as well as Ebba Svenburg (Employment and Benefits).

 

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026